5942-32-5

Basic information

• Product Name: Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester
• CAS NO: 5942-32-5
• Molecular Formula: C12H16O5
• Molecular Weight: 240.256
• Mol File: 5942-32-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 339.7±32.0 °C(Predicted)
• Density: 1.118±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester(5942-32-5)
• EPA Substance Registry System: Benzoic acid, 3-methoxy-4-(methoxymethoxy)-, ethyl ester(5942-32-5)

Safety Data

• Hazardous Substances Data: 5942-32-5(Hazardous Substances Data)

Upstream product

• 617-05-0 ethyl vanillate 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 5533-02-8 3-methoxy-4-(methoxymethoxy)benzoic acid 
• 143418-77-3 1-<3-methoxy-4-(methoxymethoxy)phenyl>ethanone 

Relevant articles and documents

MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF

Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject. Also disclosed are method for treating one or more Myc-driven cancers, including neuroblastoma, lung squamous cell carcinoma/lung adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma, acute myeloid leukemia, and breast invasive carcinoma.